Liraglutide is the original modern GLP-1 receptor agonist and remains a clinically useful option in 2026. It is daily rather than weekly, which makes it different from Wegovy and Mounjaro — and that difference matters for specific patient profiles. Here is what we use it for in our Bangkok clinic.
Liraglutide is a GLP-1 receptor agonist — an injectable peptide that mimics the action of glucagon-like peptide-1, a gut hormone released after meals. It binds to GLP-1 receptors in the pancreas, brain, and stomach, producing the same constellation of effects as other GLP-1 medications: reduced appetite, slowed gastric emptying, and glucose-dependent insulin release.
Structurally, liraglutide is the native human GLP-1 sequence with a 16-carbon fatty acid chain attached. This fatty acid binds to albumin in your bloodstream, protecting the molecule from rapid enzymatic degradation and extending its half-life from about two minutes (native GLP-1) to approximately 13 hours. That's long enough for once-daily injection — but short enough that weekly dosing requires the additional engineering found in semaglutide and tirzepatide.
Liraglutide is sold under two brand names: Saxenda for chronic weight management (maximum dose 3.0 mg daily) and Victoza for Type 2 diabetes (maximum dose 1.8 mg daily). The molecule is identical; the labels and approved maximum doses differ.
The pivotal weight-management trial for liraglutide was SCALE, published in 2015. It enrolled 3,731 non-diabetic adults with BMI ≥30 or ≥27 with comorbidities. Patients on Saxenda 3.0 mg daily lost a mean 8.0% of body weight over 56 weeks, compared to 2.6% in the placebo arm. The net pharmacologic effect — about 5.4% — established liraglutide as a viable pharmacological weight-loss option.
Responder rates: approximately 63% of patients lost at least 5% of body weight, 33% lost at least 10%. These numbers compare favorably to non-pharmacological weight loss but sit clearly below semaglutide (14.9% in STEP-1) and tirzepatide (20.9% in SURMOUNT-1).
Why is liraglutide less potent? Two reasons. First, the dose ceiling — Saxenda maxes at 3.0 mg daily, while semaglutide ramps to 2.4 mg weekly with similar absolute weekly exposure but more consistent receptor occupancy. Second, the engineering — semaglutide's tighter albumin binding produces steadier plasma concentrations than liraglutide's daily peak-and-trough profile. The result is the same receptor target but less continuous activation.
Saxenda titration: 0.6 mg daily for week 1, then increase by 0.6 mg each week until reaching 3.0 mg daily by week 5. Full maintenance dose is 3.0 mg daily, administered subcutaneously. Most patients self-inject in the abdomen or thigh.
Victoza titration: 0.6 mg daily for week 1, then 1.2 mg from week 2, with optional escalation to 1.8 mg for inadequate glycemic response. Lower maximum dose reflects the diabetes label rather than the weight-management label.
The clinical trade-off: daily dosing is more flexible (you can skip a day without major rebound) but requires more discipline to remember. Weekly dosing is more convenient but less forgiving of inconsistency. Patients who travel frequently, who prefer fine-grained dose adjustment, or who have GI sensitivity that benefits from daily smaller doses may prefer liraglutide.
The side-effect profile follows the GLP-1 class pattern: gastrointestinal events dominate, concentrated in the titration phase. In the SCALE trial, nausea was reported by 39% of patients at some point, vomiting by 16%, diarrhea by 21%, constipation by 19%, and abdominal pain by 6%. Most events were mild to moderate.
The discontinuation rate due to adverse events was approximately 9% — somewhat higher than the more modern weekly GLP-1s. This likely reflects the daily peak-and-trough profile producing more episodes of acute GI discomfort versus semaglutide's steadier plasma levels.
Class-level considerations apply: caution with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, monitoring for pancreatitis, and standard guidance about cessation if persistent severe abdominal pain develops. Cardiovascular safety has been demonstrated in the LEADER trial — liraglutide reduces major adverse cardiac events in high-risk Type 2 diabetes populations.
In our Bangkok clinic, liraglutide remains useful for specific patient profiles even though weekly GLP-1s now dominate. The clinical situations where we consider liraglutide first include the following.
Patients who prefer daily dosing — some people find a daily routine easier to maintain than a weekly schedule. The discipline of injection at the same time each day becomes part of the routine rather than a separate event to remember.
Patients with GI sensitivity who have failed weekly dosing — smaller daily exposures can be more tolerable than larger weekly peaks for some patients.
Patients with diabetes prioritizing the longest cardiovascular safety record — Victoza's LEADER trial provides mature cardiovascular outcome data.
Patients who have stopped weekly GLP-1 and need a step-down option — daily liraglutide can serve as a bridging therapy during structured discontinuation.
For most weight-loss-focused patients in 2026, however, our default starting point is Wegovy or Mounjaro rather than Liraglutide. The potency gap is too large to ignore when the goal is meaningful weight loss.
If you're considering Liraglutide and want to compare options, the relevant alternatives in 2026 are clear.
For weight loss with a weekly dosing schedule, Wegovy (semaglutide 2.4 mg weekly) typically delivers approximately 14.9% mean weight loss — roughly double liraglutide's 6-8%. For maximum weight loss, Mounjaro (tirzepatide) typically delivers approximately 20.9%.
For diabetes-focused therapy with the longest track record, Victoza (liraglutide 1.8 mg daily) remains appropriate — but for most newly-diagnosed patients in 2026, semaglutide-based Ozempic or tirzepatide-based Mounjaro offer stronger glycemic and weight outcomes.
We cover the broader class picture in GLP-1 Medications Explained, and the cross-comparison details in Mounjaro vs Wegovy.
"Liraglutide is the elder of the family. Less potent than the newer molecules, but more proven. We use it when the patient and the molecule are the right match — not as a default starting point."
Authentic Liraglutide — Saxenda for weight management, Victoza for diabetes — is available in Thailand through licensed pharmacies with cold-chain delivery. The molecule must be refrigerated; once in use, it's stable at room temperature for up to 30 days. Pricing in Thailand is competitive with regional Asia-Pacific markets and meaningfully below US cash-pay rates. Doctor-led titration ensures the daily dose schedule is followed correctly.
Yes. Saxenda is the brand name for liraglutide 3.0 mg daily used for chronic weight management. Victoza is the brand name for liraglutide 1.8 mg max used for Type 2 diabetes. Same molecule, different doses and labels.
Average about 6-8% of body weight at the Saxenda 3.0 mg dose over 56 weeks in the SCALE trial. Less than semaglutide (14.9%) or tirzepatide (20.9%). Individual results depend on starting BMI, dose tolerance, and adherence.
Liraglutide has a 13-hour plasma half-life. Modern weekly GLP-1s like semaglutide have 7-day half-lives thanks to additional engineering. The shorter half-life of liraglutide requires daily dosing to maintain receptor occupancy.
It depends on your routine. Daily dosing builds into your morning or evening routine and becomes automatic. Weekly dosing is fewer total injections but requires remembering one specific day. Patient preference varies.
All three have well-characterized safety profiles. Liraglutide has the longest cumulative human exposure (since 2010), but semaglutide and tirzepatide have added their own substantial safety data. No clear safety advantage to liraglutide in 2026.
Yes. Most patients restart at the lowest dose of the new molecule (Wegovy 0.25 mg or Mounjaro 2.5 mg) and titrate up. There is no fixed washout period required for the switch.
Yes. Authentic Saxenda (Novo Nordisk) and Victoza (Novo Nordisk) are available through licensed Thai pharmacies with cold-chain delivery. Doctor-led titration is required.
Rarely in non-diabetic patients. The GLP-1 mechanism is glucose-dependent — insulin release is triggered only when blood sugar is elevated. Patients with diabetes already on insulin or sulfonylureas need dose review.
Refrigerated at 2-8°C until first use. Once in use, the pen can be kept at room temperature (below 30°C) for up to 30 days. Avoid direct sunlight and never freeze.
Take the missed dose as soon as you remember on the same day. Skip it entirely if more than 12 hours have passed and continue with the next scheduled dose. Do not double-dose.
A 30-minute consultation evaluates whether daily liraglutide fits your goals — or whether a weekly option would serve you better.
Request consultation